Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 168, Issue 3, 2015, Pages 395-404

  Sutton, Rosemary ^a   Shaw, Peter J ^b   Venn, Nicola C ^a   Law, Tamara ^a   Dissanayake, Anuruddhika ^a   Kilo, Tatjana ^b   Haber, Michelle ^a   Norris, Murray D ^a   Fraser, Chris ^c   Alvaro, Frank ^d   Revesz, Tamas ^e   Trahair, Toby N ^a,f   Dalla Pozza, Luciano ^b   Marshall, Glenn M ^a,f   O'Brien, Tracey A ^a,f  

^a University of New South Wales   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

IKZF1; Acute lymphoblastic leukaemia; Bone marrow transplantation; Childhood leukaemia; Minimal residual disease

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B CELL LEUKEMIA; BCR ABL1 GENE; CANCER INCIDENCE; CANCER PROGNOSIS; CHILD; CHILD HEALTH CARE; CHILDHOOD CANCER; DISEASE FREE SURVIVAL; ETV6 RUNX1 GENE; FEMALE; GENE; HUMAN; KMT2A GENE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; T CELL LEUKEMIA; TREATMENT FAILURE; CLINICAL TRIAL; GENE DELETION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; FEMALE; GENE DELETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IKAROS TRANSCRIPTION FACTOR; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84921433735     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13142     Document Type: Article

References (43)

1. Bader, P., Kreyenberg, H., Henze, G.H., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., Sykora, K.W., Holter, W., Kabisch, H., Klingebiel, T. & von Stackelberg, A. (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology, 27, 377-384.
2. Bajwa, R., Schechter, T., Soni, S., Gassas, A., Doyle, J., Sisler, I., Godder, K., Tatman, D., Rumelhart, S., Domm, J., Miao, Y. & Frangoul, H. (2013) Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplantation, 48, 661-665.
3. Balduzzi, A., Valsecchi, M.G., Uderzo, C., De Lorenzo, P., Klingebiel, T., Peters, C., Stary, J., Felice, M.S., Magyarosy, E., Conter, V., Reiter, A., Messina, C., Gadner, H. & Schrappe, M. (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet, 366, 635-642.
4. Balduzzi, A., De Lorenzo, P., Schrauder, A., Conter, V., Uderzo, C., Peters, C., Klingebiel, T., Stary, J., Felice, M.S., Magyarosy, E., Schrappe, M., Dini, G., Gadner, H. & Valsecchi, M.G. (2008) Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica, 93, 925-929.
5. Balduzzi, A., Di Maio, L., Silvestri, D., Songia, S., Bonanomi, S., Rovelli, A., Conter, V., Biondi, A., Cazzaniga, G. & Valsecchi, M.G. (2014) Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? British Journal of Haematology, 164, 396-408.
6. Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E.M., Terruzzi, E., Fabris, P., Cassibba, V., Lambertenghi-Deliliers, G., Cortelezzi, A., Bosi, A., Gianfaldoni, G., Ciceri, F., Bernardi, M., Gallamini, A., Mattei, D., Di Bona, E., Romani, C., Scattolin, A.M., Barbui, T. & Rambaldi, A. (2009) Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood, 113, 4153-4162.
7. Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N. & Camitta, B.M. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 111, 5477-5485.
8. Bruggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O.G., Asnafi, V., Baruchel, A., Bassan, R., Benoit, Y., Biondi, A., Cave, H., Dombret, H., Fielding, A.K., Foa, R., Gokbuget, N., Goldstone, A.H., Goulden, N., Henze, G., Hoelzer, D., Janka-Schaub, G.E., Macintyre, E.A., Pieters, R., Rambaldi, A., Ribera, J.M., Schmiegelow, K., Spinelli, O., Stary, J., von Stackelberg, A., Kneba, M., Schrappe, M. & van Dongen, J.J. (2010) Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 24, 521-535.
9. van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does- van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731-1738.
10. Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grumayer, R., van der Velden, V., Fischer, S., Stanulla, M., Basso, G., Niggli, F.K., Schafer, B.W., Sutton, R., Koehler, R., Zimmermann, M., Valsecchi, M.G., Gadner, H., Masera, G., Schrappe, M., van Dongen, J.J., Biondi, A. & Bartram, C.R. (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 22, 771-782.
11. Fronkova, E., Muzikova, K., Mejstrikova, E., Kovac, M., Formankova, R., Sedlacek, P., Hrusak, O., Stary, J. & Trka, J. (2008) B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplantation, 42, 187-196.
12. Gokbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.A., Huttmann, A., Kobbe, G., Kreuzer, K.A., Leimer, L., Reichle, A., Schaich, M., Schwartz, S., Serve, H., Starck, M., Stelljes, M., Stuhlmann, R., Viardot, A., Wendelin, K., Freund, M. & Hoelzer, D. (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 120, 2032-2041.
13. Goldstone, A.H. & Rowe, J.M. (2009) Transplantation in adult ALL. Hematology/the Education Program of the American Society of Hematology, 2009, 593-601.
14. Gooley, T.A., Chien, J.W., Pergam, S.A., Hingorani, S., Sorror, M.L., Boeckh, M., Martin, P.J., Sandmaier, B.M., Marr, K.A., Appelbaum, F.R., Storb, R. & McDonald, G.B. (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. New England Journal of Medicine, 363, 2091-2101.
15. Goulden, N., Bader, P., Van Der Velden, V., Moppett, J., Schilham, M., Masden, H.O., Krejci, O., Kreyenberg, H., Lankester, A., Revesz, T., Klingebiel, T. & Van Dongen, J. (2003) Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. British Journal of Haematology, 122, 24-29.
16. Hunger, S.P., Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J., Reaman, G.H. & Carroll, W.L. (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of Clinical Oncology, 30, 1663-1669.
17. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998a) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072-4079.
18. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Harris, E.L., Garland, R.J., Jones, C.G., Grandage, V.L., Rowbottom, A.W., Green, A.F., Clarke, E., Lankester, A.W., Potter, M.N., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998b) Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. British Journal of Haematology, 102, 860-871.
19. Kreyenberg, H., Eckert, C., Yarkin, Y., Reising, M., Willasch, A., Handgretinger, R., Kremens, B., von Stackelberg, A., Henze, G., Klingebiel, T. & Bader, P. (2009) Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation. Leukemia, 23, 1355-1358.
20. Lankester, A.C., Bierings, M.B., van Wering, E.R., Wijkhuijs, A.J., de Weger, R.A., Wijnen, J.T., Vossen, J.M., Versluys, B., Egeler, R.M., van Tol, M.J., Putter, H., Revesz, T., van Dongen, J.J., van der Velden, V.H. & Schilham, M.W. (2010) Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia, 24, 1462-1469.
21. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
22. Loren, A.W. & Porter, D.L. (2008) Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation, 41, 483-493.
23. Marshall, G.M., Dalla Pozza, L., Sutton, R., Ng, A., de Groot-Kruseman, H.A., van der Velden, V.H., Venn, N.C., van den Berg, H., de Bont, E.S., Maarten Egeler, R., Hoogerbrugge, P.M., Kaspers, G.J., Bierings, M.B., van der Schoot, E., van Dongen, J., Law, T., Cross, S., Mueller, H., de Haas, V., Haber, M., Revesz, T., Alvaro, F., Suppiah, R., Norris, M.D. & Pieters, R. (2013) High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia, 27, 1497-1503.
24. Mateos, M.K., O'Brien, T.A., Oswald, C., Gabriel, M., Ziegler, D.S., Cohn, R.J., Russell, S.J., Barbaric, D., Marshall, G.M. & Trahair, T.N. (2013) Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatric Blood and Cancer, 60, 1520-1527.
25. Maus, M.V., Grupp, S.A., Porter, D.L. & June, C.H. (2014) Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625-2635.
26. Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., Cave, H., Clappier, E., Mass-Malo, K., Zuna, J., Trka, J., De Braekeleer, E., De Braekeleer, M., Oh, S.H., Tsaur, G., Fechina, L., van der Velden, V.H., van Dongen, J.J., Delabesse, E., Binato, R., Silva, M.L., Kustanovich, A., Aleinikova, O., Harris, M.H., Lund-Aho, T., Juvonen, V., Heidenreich, O., Vormoor, J., Choi, W.W., Jarosova, M., Kolenova, A., Bueno, C., Menendez, P., Wehner, S., Eckert, C., Talmant, P., Tondeur, S., Lippert, E., Launay, E., Henry, C., Ballerini, P., Lapillone, H., Callanan, M.B., Cayuela, J.M., Herbaux, C., Cazzaniga, G., Kakadiya, P.M., Bohlander, S., Ahlmann, M., Choi, J.R., Gameiro, P., Lee, D.S., Krauter, J., Cornillet-Lefebvre, P., Te Kronnie, G., Schafer, B.W., Kubetzko, S., Alonso, C.N., zur Stadt, U., Sutton, R., Venn, N.C., Izraeli, S., Trakhtenbrot, L., Madsen, H.O., Archer, P., Hancock, J., Cerveira, N., Teixeira, M.R., Lo Nigro, L., Moricke, A., Stanulla, M., Schrappe, M., Sedek, L., Szczepanski, T., Zwaan, C.M., Coenen, E.A., van den Heuvel-Eibrink, M.M., Strehl, S., Dworzak, M., Panzer-Grumayer, R., Dingermann, T., Klingebiel, T. & Marschalek, R. (2013) The MLL recombinome of acute leukemias in 2013. Leukemia, 27, 2165-2176.
27. Moore, A.S., Shaw, P.J., Hallahan, A.R., Carter, T.L., Kilo, T., Nivison-Smith, I., O'Brien, T.A., Tapp, H., Teague, L., Wilson, S.R. & Tiedemann, K. (2009) Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Medical Journal of Australia, 190, 121-125.
28. Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. & Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 1094-1104.
29. Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A. & Downing, J.R. (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453, 110-114.
30. Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A.V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., Green, N., Revesz, T., Darbyshire, P., Love, S. & Saha, V. (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet, 376, 2009-2017.
31. Pulsipher, M.A., Boucher, K.M., Wall, D., Frangoul, H., Duval, M., Goyal, R.K., Shaw, P.J., Haight, A.E., Grimley, M., Grupp, S.A., Kletzel, M. & Kadota, R. (2009) Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood, 114, 1429-1436.
32. Schilham, M.W., Balduzzi, A. & Bader, P. (2005) Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplantation, 35, S49-S52.
33. Schrauder, A., von Stackelberg, A., Schrappe, M., Cornish, J. & Peters, C. (2008) Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplantation, 41, S71-S74.
34. Schultz, K.R., Carroll, A., Heerema, N.A., Bowman, W.P., Aledo, A., Slayton, W.B., Sather, H., Devidas, M., Zheng, H.W., Davies, S.M., Gaynon, P.S., Trigg, M., Rutledge, R., Jorstad, D., Winick, N., Borowitz, M.J., Hunger, S.P., Carroll, W.L. & Camitta, B. (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group Study AALL0031. Leukemia, 28, 1467-1471.
35. Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., Zanotti, M.C., Oldani, E., Grassi, A., Intermesoli, T., Mico, C., Rossi, G., Fabris, P., Lambertenghi-Deliliers, G., Angelucci, E., Barbui, T., Bassan, R. & Rambaldi, A. (2007) Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica, 92, 612-618.
36. Sramkova, L., Muzikova, K., Fronkova, E., Krejci, O., Sedlacek, P., Formankova, R., Mejstrikova, E., Stary, J. & Trka, J. (2007) Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 48, 93-100.
37. Sutton, R., Lonergan, M., Tapp, H., Venn, N.C., Haber, M., Norris, M.D., O'Brien, T.A., Alvaro, F. & Revesz, T. (2008a) Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia. Leukemia, 22, 1463-1465.
38. Sutton, R., Bahar, A.Y., Kwan, E., Giles, J.E., Venn, N.C., Tran, S., Hackenberg, N., Pozza, L.D., Marshall, G.M., Haber, M., van der Velden, V.H.J. & Norris, M.D. (2008b) Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-[kappa] and heavy-chain gene rearrangements. Leukemia, 22, 2265-2267.
39. Sutton, R., Venn, N.C., Tolisano, J., Bahar, A.Y., Giles, J.E., Ashton, L.J., Teague, L., Rigutto, G., Waters, K., Marshall, G.M., Haber, M. & Norris, M.D. (2009) Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 146, 292-299.
40. van der Velden, V.H.J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E. & van Dongen, J.J.M. (2007) Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604-611.
41. Venn, N.C., van der Velden, V.H., de Bie, M., Waanders, E., Giles, J.E., Law, T., Kuiper, R.P., de Haas, V., Mullighan, C.G., Haber, M., Marshall, G.M., Md, N., van Dongen, J.J. & Sutton, R. (2012) Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia, 26, 1414-1416.
42. Verneris, M.R. & Burke, M.J. (2010) Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Current Hematologic Malignancy Reports, 5, 157-162.
43. Waanders, E., van der Velden, V.H., van der Schoot, C.E., van Leeuwen, F.N., van Reijmersdal, S.V., de Haas, V., Veerman, A.J., van Kessel, A.G., Hoogerbrugge, P.M., Kuiper, R.P. & van Dongen, J.J. (2011) Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia, 25, 254-258.